Gruenenthal looks beyond pain for transformative deals

Speaking at the 2017 Biotech Showcase™ in San Francisco, Grünenthal CEO Gabriel Baertschi reveals his ambition to grow the company from its current EUR 1.4 billion a year revenues to EUR 2 billion by 2022, launching four new medicines by that date, consolidating its position as a leader in pain therapeutics, while entering new areas. Consequently, he was at the meeting seeking new opportunities in indications adjacent to pain including inflammation, arthritis, gout, as well as Parkinson’s disease and rare diseases such as Duchenne muscular dystrophy. Looking at both early stage preclinical projects and later stage clinical assets, Baertschi is keen to expand the company’s global footprint. Already with a significant presence in Europe and Latin America, the company wants to expand in the US while entering the Japanese market for the first time